EN DE
Watch TWi Biotechnology, Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

TWi Biotechnology, Inc. (6610) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of TWi Biotechnology, Inc. stock TWD 21.79, price TWD 17.80, upside +22.4%, quality 35 out of 100. Rating: undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0006610009

TB TWi Biotechnology, Inc. logo Thin data Nov 5, 2026

TWi Biotechnology, Inc.

6610 · TWO
Speculative

The stock costs 18% less than our calculation considers fair.

Fair value 21.79 TWD · Undervalued
Mixed vs. peers (4/7)
Quality 35/100
Weak Growth
Negative free cash flow
Narrow moat 9/100
Thin data
⚠ Dilution
Watch TWi Biotechnology, Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

52.40 TWD 15.55 TWD Fair Value 21.79 TWD Dec 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.

How to read this chart

11‑month range 15.55 TWD – 52.40 TWD · fair‑value band 14.52 TWD – 27.37 TWD · the 17.80 TWD price screens below the 21.79 TWD fair value. As of Nov 5, 2026.

Follow TWi Biotechnology in your weekly email

Every Wednesday you see whether TWi Biotechnology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan.

Show moreShow less

The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseases.

It has a drug development agreement with Hong Kong Winhealth Pharma Group Co., Limited. in Mainland China, Hong Kong, and Macao markets. TWi Biotechnology, Inc. was founded in 2010 and is based in Taipei, Taiwan.

Stock analysis

TWi Biotechnology, Inc. (6610) currently trades at 17.80 TWD, while our model-based Fair Value estimate is 21.79 TWD, implying the stock looks roughly 18% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 14.52 TWD (bear) to 27.37 TWD (bull), the price of 17.80 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

TWi Biotechnology, Inc. reported revenue of 0 TWD in FY2025 versus 66.4M TWD in FY2021. Reported net income was −358M TWD in FY2025.

Key figures

Market cap 3.6B TWD (≈ $110M) Micro · EPS (TTM) −1.73 TWD · Return on equity −80.3% · Return on assets (EBIT) −41.8% (5-year average) · Free cash flow −293M TWD · Net cash 111M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 66% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 22%, 6610 screens cheaper than that median.

Fair Value models

Bear 14.52 TWD Fair Value 21.79 TWD Bull 27.37 TWD
Price 17.80 TWD · Upside +22.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 0.5200 TWD 0.7800 TWD 0.9800 TWD 52
All 1 models by family
Asset-Based
NCAV (Graham) 0.5200 TWD 0.7800 TWD 0.9800 TWD 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 20
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 29
How calm the share price moves, does not count
Price momentum 4
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 15
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 6610, get fair value alerts →

Compare TWi Biotechnology, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 35 · Below median
Fair Value upside +20.4% · Top 25%
Profitability
Return on assets −49.4% · Bottom 25%
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.18× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)61 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 6610
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 6610
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 6610
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 6610
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 6610
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 6610
argenx SE ARGX $927.21 $908.40 −2% vs 6610
CSL Limited CSL A$200.77 A$183.04 −9% vs 6610
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 6610
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 6610

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

TWi Biotechnology, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "TWi Biotechnology, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/6610

Frequently asked questions

Is TWi Biotechnology, Inc. (6610) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of 21.79 TWD versus a price of 17.80 TWD, about +22% upside (undervalued).
What is the fair value of 6610?
Our model-based fair value for TWi Biotechnology, Inc. is 21.79 TWD (as of Nov 5, 2026), built from audited fundamentals. The current price: 17.80 TWD.
What is the quality score of 6610?
TWi Biotechnology, Inc. has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for TWi Biotechnology, Inc. (6610)?
Our model-based price target is the fair value of 21.79 TWD (as of Nov 5, 2026) from 1 valuation models. Cautious scenario 14.52 TWD, optimistic scenario 27.37 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the TWi Biotechnology, Inc. stock forecast for 2026?
Our models put fair value at 21.79 TWD, about +22% upside versus a price of 17.80 TWD (undervalued). Cautious scenario 14.52 TWD, optimistic scenario 27.37 TWD. The calculation is refreshed regularly with new filings.
What is the intrinsic value of TWi Biotechnology, Inc. (6610)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For TWi Biotechnology, Inc. it is 21.79 TWD per share (as of Nov 5, 2026), against a price of 17.80 TWD. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is TWi Biotechnology, Inc. stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 6610 trades below its calculated fair value: price 17.80 TWD, fair value 21.79 TWD, a gap of about +22% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6610?
No. The price is what the market pays today (17.80 TWD); the fair value is what the company's own numbers justify (21.79 TWD). For TWi Biotechnology, Inc. the two are 3.99 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is TWi Biotechnology, Inc. worth?
The market values TWi Biotechnology, Inc. at about 3.6B TWD (market capitalisation, as of Nov 5, 2026). Per share that is 17.80 TWD; our models calculate a fair value of 21.79 TWD per share.
What do the bullish and bearish scenarios say about 6610?
Our models span a range for TWi Biotechnology, Inc.: cautious scenario 14.52 TWD, base 21.79 TWD, optimistic 27.37 TWD per share (as of Nov 5, 2026, price 17.80 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of TWi Biotechnology, Inc. (6610)?
Balance-sheet figures for TWi Biotechnology, Inc. (as of Nov 5, 2026): return on equity −80.3%. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is 6610 from its 52-week high?
TWi Biotechnology, Inc. trades at 17.80 TWD, about 66% below its 52-week high of 52.40 TWD and 14% above the low of 15.55 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 21.79 TWD is for.
Which stocks are comparable to TWi Biotechnology, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is TWi Biotechnology, Inc. stock attractive at the current price?
The data as of Nov 5, 2026: price 17.80 TWD, calculated fair value 21.79 TWD (+22%), Quality Score 35/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6610 calculated?
We run TWi Biotechnology, Inc. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 21.79 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. TWi Biotechnology, Inc. currently trades 18% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of TWi Biotechnology, Inc. (6610)?
The closing price on Nov 9, 2026 was 17.80 TWD. Our model-based fair value is 21.79 TWD, about +22% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with TWi Biotechnology, Inc. right now?
A fairly wide model range (14.52 TWD to 27.37 TWD) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of TWi Biotechnology, Inc.

How large is the market capitalisation of TWi Biotechnology, Inc. (6610)?
The market capitalisation of TWi Biotechnology, Inc. is 3.6B TWD (≈ $110M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of TWi Biotechnology, Inc. (6610)?
Earnings per share at TWi Biotechnology, Inc. are −1.73 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of TWi Biotechnology, Inc. (6610)?
The return on equity (ROE) of TWi Biotechnology, Inc. is −80.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of TWi Biotechnology, Inc. (6610)?
On an EBIT basis the return on assets of TWi Biotechnology, Inc. is −41.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does TWi Biotechnology, Inc. (6610) generate?
The free cash flow of TWi Biotechnology, Inc. is −293M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does TWi Biotechnology, Inc. (6610) hold?
TWi Biotechnology, Inc. holds more cash than debt, 111M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch TWi Biotechnology, Inc. in the live analysis

One click puts TWi Biotechnology, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.